Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.

ABSTRACT:

Background

Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.

Objectives

To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).

Methods

We performed a retrospective study on consecutive patients with CAT recruited between 2008 and 2019. The primary and secondary outcomes were recurrent VTE at 6 and 12 months, respectively. Sensitivity analyses were conducted to investigate the possible heterogeneity of these effects.

Results

A total of 311 patients were included, among whom 33.4% h

SUBMITTER: Barca-Hernando M 

PROVIDER: S-EPMC10099299 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature